CA2840336C - Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome - Google Patents
Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome Download PDFInfo
- Publication number
- CA2840336C CA2840336C CA2840336A CA2840336A CA2840336C CA 2840336 C CA2840336 C CA 2840336C CA 2840336 A CA2840336 A CA 2840336A CA 2840336 A CA2840336 A CA 2840336A CA 2840336 C CA2840336 C CA 2840336C
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl group
- hydrogen
- halogen atoms
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000035895 Guillain-Barré syndrome Diseases 0.000 title claims abstract description 59
- 206010049567 Miller Fisher syndrome Diseases 0.000 title claims abstract description 59
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 45
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title description 6
- 229940124597 therapeutic agent Drugs 0.000 title description 4
- 230000000069 prophylactic effect Effects 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 189
- 239000001257 hydrogen Substances 0.000 claims abstract description 189
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract description 185
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 70
- 125000001424 substituent group Chemical group 0.000 claims abstract description 45
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 40
- 230000003405 preventing effect Effects 0.000 claims abstract description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000005843 halogen group Chemical group 0.000 claims description 219
- 150000001875 compounds Chemical class 0.000 claims description 158
- 150000003839 salts Chemical class 0.000 claims description 143
- 125000003545 alkoxy group Chemical group 0.000 claims description 114
- 150000002431 hydrogen Chemical group 0.000 claims description 101
- 125000000217 alkyl group Chemical group 0.000 claims description 83
- -1 amino, carboxyl Chemical group 0.000 claims description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 50
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 239000004480 active ingredient Substances 0.000 claims description 35
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 32
- 125000002252 acyl group Chemical group 0.000 claims description 26
- 125000004442 acylamino group Chemical group 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 17
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 17
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 15
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 15
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 12
- 125000001246 bromo group Chemical group Br* 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- UBKXNDABCANVQN-UHFFFAOYSA-N potassium;5-[3-(2h-tetrazol-5-yl)phenyl]-1h-benzo[g][1,5]benzodiazepine-2,4-dione Chemical compound [K].C12=CC=C3C=CC=CC3=C2NC(=O)CC(=O)N1C(C=1)=CC=CC=1C1=NN=NN1 UBKXNDABCANVQN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 102100037601 P2X purinoceptor 4 Human genes 0.000 abstract description 19
- 101710189967 P2X purinoceptor 4 Proteins 0.000 abstract description 17
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract description 9
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract description 9
- 229960002296 paroxetine Drugs 0.000 abstract description 9
- 239000002464 receptor antagonist Substances 0.000 abstract description 6
- 229940044551 receptor antagonist Drugs 0.000 abstract description 6
- RTXTUGWLUYJQCG-UHFFFAOYSA-N 1h-diazepine-6,7-dione Chemical class O=C1C=CC=NNC1=O RTXTUGWLUYJQCG-UHFFFAOYSA-N 0.000 abstract description 3
- 125000003118 aryl group Chemical group 0.000 description 22
- 229910052736 halogen Inorganic materials 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 11
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 125000001544 thienyl group Chemical group 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 230000037040 pain threshold Effects 0.000 description 7
- 238000011552 rat model Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002330 subarachnoid space Anatomy 0.000 description 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
- 230000007845 axonopathy Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 206010029240 Neuritis Diseases 0.000 description 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960001653 citalopram Drugs 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 229960004038 fluvoxamine Drugs 0.000 description 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 208000022084 motor paralysis Diseases 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 150000003536 tetrazoles Chemical group 0.000 description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 206010013886 Dysaesthesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 108010068647 P2 peptide Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 2
- 208000020764 Sensation disease Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 210000003019 respiratory muscle Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- IQDWSLIUMJAMEM-UHFFFAOYSA-N 2-[(2,4-dichlorophenoxy)methyl]-1-(4-propan-2-yloxyphenyl)piperazine Chemical compound C1=CC(OC(C)C)=CC=C1N1C(COC=2C(=CC(Cl)=CC=2)Cl)CNCC1 IQDWSLIUMJAMEM-UHFFFAOYSA-N 0.000 description 1
- WIXSJBXAAZXTAL-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(2,3-dihydro-1h-inden-5-yl)piperazine Chemical compound C1=CC(Cl)=CC=C1OCC1N(C=2C=C3CCCC3=CC=2)CCNC1 WIXSJBXAAZXTAL-UHFFFAOYSA-N 0.000 description 1
- BHQDNFQAAXYXSM-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(2,4,6-trimethylphenyl)piperazine Chemical compound CC1=CC(C)=CC(C)=C1N1C(COC=2C=CC(Cl)=CC=2)CNCC1 BHQDNFQAAXYXSM-UHFFFAOYSA-N 0.000 description 1
- SBXXLZGTIXMTHS-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1C(COC=2C=CC(Cl)=CC=2)CNCC1 SBXXLZGTIXMTHS-UHFFFAOYSA-N 0.000 description 1
- WIRYHUBSRFJYBY-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(3-methoxyphenyl)piperazine Chemical compound COC1=CC=CC(N2C(CNCC2)COC=2C=CC(Cl)=CC=2)=C1 WIRYHUBSRFJYBY-UHFFFAOYSA-N 0.000 description 1
- JMXLLKKEWDQQQU-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(3-propan-2-ylphenyl)piperazine Chemical compound CC(C)C1=CC=CC(N2C(CNCC2)COC=2C=CC(Cl)=CC=2)=C1 JMXLLKKEWDQQQU-UHFFFAOYSA-N 0.000 description 1
- UQJLZJUCOCNFRQ-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(4-propan-2-yloxyphenyl)piperazine Chemical compound C1=CC(OC(C)C)=CC=C1N1C(COC=2C=CC(Cl)=CC=2)CNCC1 UQJLZJUCOCNFRQ-UHFFFAOYSA-N 0.000 description 1
- JIIPHQRRJICXOS-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(4-propan-2-ylphenyl)piperazine Chemical compound C1=CC(C(C)C)=CC=C1N1C(COC=2C=CC(Cl)=CC=2)CNCC1 JIIPHQRRJICXOS-UHFFFAOYSA-N 0.000 description 1
- SQMHGIUVJCNERI-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-1-(4-propylphenyl)piperazine Chemical compound C1=CC(CCC)=CC=C1N1C(COC=2C=CC(Cl)=CC=2)CNCC1 SQMHGIUVJCNERI-UHFFFAOYSA-N 0.000 description 1
- YPTQLKZKLIXBCG-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfanylmethyl]-1-(4-propan-2-ylphenyl)piperazine Chemical compound C1=CC(C(C)C)=CC=C1N1C(CSC=2C=CC(Cl)=CC=2)CNCC1 YPTQLKZKLIXBCG-UHFFFAOYSA-N 0.000 description 1
- BOXJZPIYFHZZTR-UHFFFAOYSA-N 2-[[4-[(2-methylpropan-2-yl)oxy]phenoxy]methyl]-1-(4-propan-2-yloxyphenyl)piperazine Chemical compound C1=CC(OC(C)C)=CC=C1N1C(COC=2C=CC(OC(C)(C)C)=CC=2)CNCC1 BOXJZPIYFHZZTR-UHFFFAOYSA-N 0.000 description 1
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical group O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 1
- LYGLYFUBLZCHCT-UHFFFAOYSA-N 2h-1,2,4-oxadiazole-5-thione Chemical group SC1=NC=NO1 LYGLYFUBLZCHCT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101001098179 Homo sapiens P2X purinoceptor 4 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000030137 articulation disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001474 neuritogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011116965 | 2011-05-25 | ||
| JP2011-116965 | 2011-05-25 | ||
| PCT/JP2012/063424 WO2012161301A1 (ja) | 2011-05-25 | 2012-05-25 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2840336A1 CA2840336A1 (en) | 2012-11-29 |
| CA2840336C true CA2840336C (en) | 2020-06-30 |
Family
ID=47217366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2840336A Active CA2840336C (en) | 2011-05-25 | 2012-05-25 | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20140163013A1 (enExample) |
| EP (1) | EP2716302B1 (enExample) |
| JP (2) | JP6325252B2 (enExample) |
| CA (1) | CA2840336C (enExample) |
| ES (1) | ES2653244T3 (enExample) |
| WO (1) | WO2012161301A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012060397A1 (ja) * | 2010-11-05 | 2012-05-10 | 国立大学法人九州大学 | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 |
| PL2803662T3 (pl) | 2012-01-13 | 2017-09-29 | Nippon Chemiphar Co., Ltd. | Antagonista receptora p2x4 |
| AU2014288116B2 (en) | 2013-07-12 | 2018-05-17 | Kyushu University | P2X4 receptor antagonist |
| ES2753422T3 (es) * | 2013-07-12 | 2020-04-08 | Nippon Chemiphar Co | Antagonista de receptor P2X4 |
| WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
| WO2019222850A1 (en) * | 2018-05-23 | 2019-11-28 | Wex Pharmaceuticals Inc. | Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain |
| JP2022163241A (ja) * | 2019-09-13 | 2022-10-26 | 日本ケミファ株式会社 | Ｐ２ｘ４受容体拮抗剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312969A1 (de) * | 2003-03-24 | 2004-10-07 | Bayer Healthcare Ag | Benzofuro-1,4-diazepin-2-on-Derivate |
| JP2009057281A (ja) * | 2005-12-19 | 2009-03-19 | Nippon Chemiphar Co Ltd | Ｐ２ｘ４受容体拮抗剤 |
| JP2009062278A (ja) * | 2005-12-29 | 2009-03-26 | Nippon Chemiphar Co Ltd | Ｐ２ｘ４受容体拮抗剤 |
| JPWO2008020651A1 (ja) * | 2006-08-17 | 2010-01-07 | 国立大学法人九州大学 | Ｐ２ｘ４受容体アンタゴニスト |
| EP2058304A4 (en) * | 2006-08-25 | 2012-10-10 | Nippon Chemiphar Co | P2X4 RECEPTOR ANTAGONIST |
| WO2008079228A1 (en) * | 2006-12-20 | 2008-07-03 | Danisco Us, Inc., Genencor Division | Assays for improved fungal strains |
| JP2012087053A (ja) * | 2009-02-03 | 2012-05-10 | Nippon Chemiphar Co Ltd | ジアゼピンジオン誘導体 |
| WO2010093061A1 (ja) * | 2009-02-16 | 2010-08-19 | 日本ケミファ株式会社 | ジアゼピンジオン誘導体 |
| WO2012060397A1 (ja) * | 2010-11-05 | 2012-05-10 | 国立大学法人九州大学 | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 |
-
2012
- 2012-05-25 WO PCT/JP2012/063424 patent/WO2012161301A1/ja not_active Ceased
- 2012-05-25 CA CA2840336A patent/CA2840336C/en active Active
- 2012-05-25 ES ES12789670.2T patent/ES2653244T3/es active Active
- 2012-05-25 US US14/119,223 patent/US20140163013A1/en not_active Abandoned
- 2012-05-25 EP EP12789670.2A patent/EP2716302B1/en active Active
- 2012-05-25 JP JP2013516451A patent/JP6325252B2/ja active Active
-
2016
- 2016-10-28 US US15/337,384 patent/US20170065608A1/en not_active Abandoned
-
2017
- 2017-01-11 JP JP2017002944A patent/JP2017119702A/ja active Pending
-
2018
- 2018-10-17 US US16/163,108 patent/US20190046539A1/en not_active Abandoned
-
2022
- 2022-10-17 US US17/967,676 patent/US20230059381A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2840336A1 (en) | 2012-11-29 |
| EP2716302B1 (en) | 2017-09-27 |
| EP2716302A4 (en) | 2014-11-05 |
| US20230059381A1 (en) | 2023-02-23 |
| EP2716302A1 (en) | 2014-04-09 |
| ES2653244T3 (es) | 2018-02-06 |
| US20190046539A1 (en) | 2019-02-14 |
| JP2017119702A (ja) | 2017-07-06 |
| US20140163013A1 (en) | 2014-06-12 |
| US20170065608A1 (en) | 2017-03-09 |
| WO2012161301A1 (ja) | 2012-11-29 |
| JPWO2012161301A1 (ja) | 2014-07-31 |
| JP6325252B2 (ja) | 2018-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
| KR101607081B1 (ko) | 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약 | |
| AU2011315891B2 (en) | Compositions and methods of treating pulmonary hypertension | |
| CN102316872A (zh) | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 | |
| US12090158B2 (en) | Medicine for diabetic peripheral neuropathy | |
| JP2017014224A (ja) | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 | |
| JP2002121153A (ja) | 抑うつ及び不安のための併合療法 | |
| EP0808166A1 (fr) | Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports | |
| ES2311012T3 (es) | Ligandos del receptor d3 de la dopamina para el tratamiento de la adiccion. | |
| CN111556753A (zh) | 用于夜间尿频的治疗剂 | |
| US20120059012A1 (en) | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | |
| JP2001511763A (ja) | 尿失禁の治療のための５−ｈｔ▲下１ａ▼受容体アンタゴニストの使用 | |
| US20200368223A1 (en) | Methods for inhibiting phosphate transport | |
| WO2021021005A1 (ru) | Применение производных n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов для терапии депрессии | |
| US20230149357A1 (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease | |
| CN1997364A (zh) | 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗 | |
| WO2021203779A1 (zh) | 治疗肺动脉高压的化合物及其应用 | |
| CN120569196A (zh) | 用于控制葡萄糖水平的组合物和方法 | |
| US20070197786A1 (en) | Enantiomerically pure opioid diarylmethylpiperazine | |
| US20140302022A1 (en) | 2-carboxamide clycloamino urea derivatives for use in treating vegf-dependent diseases | |
| EA041892B1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
| AU2018229062A1 (en) | Therapeutic agent for alcohol use disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170523 |